Does Dusa Run Too Hard?
by Douglas A. McIntyre
24/7 Wall St.
Dusa Pharmaceuticals (DUSA) received "orphan drug status" for its for Levulan photodynamic therapy for the treatment of esophageal dysplasia, a disease that occurs in some patients with Barrett's esophagus, a leading cause of esophageal cancer. Orphan diseases are defined as diseases affecting fewer than 200,000 people in the United States or low prevalence is taken as prevalence of less than 5 per 10,000 in the community. Because it is hard to get back the investment in new drugs, the status may grant longer patent times or outside funding for research.
The news from Dusa pushed its stock up 60% to $4.40.
Continue article at 247WallSt.com
__________________
24/7 Wall St.
Dusa Pharmaceuticals (DUSA) received "orphan drug status" for its for Levulan photodynamic therapy for the treatment of esophageal dysplasia, a disease that occurs in some patients with Barrett's esophagus, a leading cause of esophageal cancer. Orphan diseases are defined as diseases affecting fewer than 200,000 people in the United States or low prevalence is taken as prevalence of less than 5 per 10,000 in the community. Because it is hard to get back the investment in new drugs, the status may grant longer patent times or outside funding for research.The news from Dusa pushed its stock up 60% to $4.40.
Continue article at 247WallSt.com
__________________
posted by Nico at
11:59 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home